Other formats:
BibTeX
LaTeX
RIS
@proceedings{1644938,
author = {Miklíková, Marie and Jarkovský, Jiří and Benešová, Klára and Miklík, Roman and Felšőci, Marián and Špinar, Jindřich and Dušek, Ladislav and Pařenica, Jiří},
booktitle = {Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology},
keywords = {Hyperuricaemia treatment; acute heart failure; AHEAD registry},
language = {eng},
title = {Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry},
url = {https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext},
year = {2019}
}
TY - CONF
ID - 1644938
AU - Miklíková, Marie - Jarkovský, Jiří - Benešová, Klára - Miklík, Roman - Felšőci, Marián - Špinar, Jindřich - Dušek, Ladislav - Pařenica, Jiří
PY - 2019
TI - Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry
KW - Hyperuricaemia treatment
KW - acute heart failure
KW - AHEAD registry
UR - https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext
L2 - https://academic.oup.com/eurheartj/article-abstract/40/Supplement_1/ehz748.0415/5596975?redirectedFrom=fulltext
N2 - Background Hyperuricaemia is associated with a poorer prognosis in heart failure (HF) patients. Benefits of hyperuricaemia treatment with allopurinol have not yet been confirmed in clinical practice. The aim of our work was to assess the benefit of allopurinol treatment in a large cohort of HF patients. Methods and results The prospective acute heart failure registry (AHEAD) was used to select 3,160 hospitalized patients with a known level of uric acid (UA) who were discharged in a stable condition. Hyperuricaemia was defined as UA _>500mmol/l and/or allopurinol treatment at admission. The patients were classified into three groups: without hyperuricaemia, with treated hyperuricaemia and with untreated hyperuricaemia at discharge. Two- and five-year all-cause mortality were defined as endpoints. Patients without hyperuricaemia, unlike those with hyperuricaemia, had a higher left ventricular ejection fraction, a better renal function and higher haemoglobin levels, had less frequently diabetes mellitus and atrial fibrillation, and showed better tolerance to treatment with ACEIs/ARBs and/or beta-blockers. In a primary analysis, the patients without hyperuricaemia had the highest survival rate. After using the propensity score to set up comparable groups, the patients without hyperuricaemia had a similar five-year survival rate as those with untreated hyperuricaemia (42.0% vs 39.7%, p=0.362) whereas those with treated hyperuricaemia had a poorer prognosis (32.4% survival rate; p=0.006 vs non-hyperuricaemia group and p=0.073 vs untreated group). Conclusion Hyperuricaemia was associated with an unfavourable cardiovascular risk profile in HF patients. Treatment of hyperuricaemia with low doses of allopurinol did not improve the longterm prognosis of HF patients.
ER -
MIKLÍKOVÁ, Marie, Jiří JARKOVSKÝ, Klára BENEŠOVÁ, Roman MIKLÍK, Marián FELŠ$\backslash$H OCI, Jindřich ŠPINAR, Ladislav DUŠEK and Jiří PAŘENICA. Hyperuricaemia treatment in acute heart failure patients does not improve their long-term prognosis: a propensity score matched analysis from the AHEAD registry. In \textit{Congress of the European-Society-of-Cardiology (ESC) / World Congress of Cardiology}. 2019. ISSN~0195-668X.
|
